- Public Comps
- Magis
Magis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Magis and similar public comparables like DGL Group, Enka de Colombia, Amoeba, BRAIN Biotech and more.
Magis Overview
About Magis
Magis SpA engages in the production of customized adhesive tapes, packaging products, and closure systems for disposable nappies and adult incontinence products. Its products comprise Bopp tapes, Bopet tapes, Duct tapes, Crepe tapes, and Mopp tapes.
Founded
1983
HQ

Employees
N/A
Website
Sectors
Financials (LTM)
EV
$55M
Valuation Multiples
Start free trialMagis Financials
Magis reported last 12-month revenue of $92M and EBITDA of $11M.
In the same LTM period, Magis generated $79M in gross profit, $11M in EBITDA, and $4M in net income.
Magis P&L
In the most recent fiscal year, Magis reported revenue of $92M and EBITDA of $10M.
Magis is profitable as of last fiscal year, with gross margin of 36%, EBITDA margin of 11%, and net margin of 4%.
Financial data powered by Morningstar, Inc.
Magis Stock Performance
Magis has current market cap of $63M, and enterprise value of $55M.
Market Cap Evolution
Magis' stock price is $10.98.
Magis share price increased by 1.8% in the last 30 days, and decreased by 19.3% in the last year.
Magis has an EPS (earnings per share) of $0.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55M | $63M | -0.0% | 1.8% | -3.1% | -19.3% | $0.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMagis Valuation Multiples
Magis trades at 0.6x EV/Revenue multiple, and 5.0x EV/EBITDA.
Magis Financial Valuation Multiples
As of July 19, 2026, Magis has market cap of $63M and EV of $55M.
Magis has a P/E ratio of 14.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Magis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Magis Margins & Growth Rates
Magis decreased revenue by 0% but EBITDA grew by 17% in the last fiscal year.
In the most recent fiscal year, Magis reported gross margin of 36%, EBITDA margin of 11%, and net margin of 4%.
Magis Margins
Magis Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Magis Operational KPIs
Magis' Rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Magis' Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Magis Competitors
Magis competitors include DGL Group, Enka de Colombia, Amoeba, BRAIN Biotech, eXoZymes, Elton, American Vanguard, Neochim, Northern Technologies and Holland.
Most Magis public comparables operate across Chemicals.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.5x | - | 4.8x | - | |||
| - | - | - | - | |||
| 97.1x | 14.7x | (11.0x) | (16.0x) | |||
| 1.1x | 1.1x | (83.3x) | 27.2x | |||
| - | - | (5.9x) | - | |||
| 0.4x | - | 8.5x | - | |||
| 0.6x | 0.6x | 7.3x | 7.3x | |||
| 0.0x | - | 0.3x | - | |||
This data is available for Pro users. Sign up to see all Magis competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Magis
| When was Magis founded? | Magis was founded in 1983. |
| Where is Magis headquartered? | Magis is headquartered in Italy. |
| Is Magis publicly listed? | Yes, Magis is a public company listed on Borsa Italiana. |
| What is the stock symbol of Magis? | Magis trades under MGS ticker. |
| When did Magis go public? | Magis went public in 2022. |
| Who are competitors of Magis? | Magis main competitors include DGL Group, Enka de Colombia, Amoeba, BRAIN Biotech, eXoZymes, Elton, American Vanguard, Neochim, Northern Technologies, Holland. |
| What is the current market cap of Magis? | Magis' current market cap is $63M. |
| What is the current revenue of Magis? | Magis' last 12 months revenue is $92M. |
| What is the current revenue growth of Magis? | Magis revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Magis? | Current revenue multiple of Magis is 0.6x. |
| What is the current EBITDA of Magis? | Magis' last 12 months EBITDA is $11M. |
| What is Magis' EBITDA margin? | Magis' last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Magis? | Current EBITDA multiple of Magis is 5.0x. |
| What is the current FCF of Magis? | Magis' last 12 months FCF is ($2M). |
| What is Magis' FCF margin? | Magis' last 12 months FCF margin is (2%). |
| What is the current EV/FCF multiple of Magis? | Current FCF multiple of Magis is (36.0x). |
| How many companies Magis has acquired to date? | Magis hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Magis has invested to date? | Magis hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Magis
Lists including Magis
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




